NeuroDerm, A Mitsubishi Tanabe Pharma Group Company
Recreating a future for Parkinson's
Recreating a future for Parkinson's
NeuroDerm, A Mitsubishi Tanabe Pharma Group Company is an agile and entrepreneurial R&D company with a mission to drive healthcare innovation and patient-centric solutions through Pharma & MedTech integration. Founded in 2003 and headquartered in Israel, NeuroDerm is focused on developing next-generation drug-device combination solutions for central nervous system disorders to make a meaningful difference in patients’ lives and drive future healthcare connectivity.
The company's slogan "Recreating a future for Parkinson's" emphasizes its dedication to addressing the challenges of the future healthcare and wellbeing ecosystem. NeuroDerm is passionately driven to reduce disease burden and improve the quality of life of patients and their families through innovative drug-device combination therapies and technologies. Its last investment of $75.00M in Post-IPO Equity was received on 07 December 2016. The investors in this last investment round are not specified.
With its focus on Biotechnology, Health Care, and Pharmaceutical industries, NeuroDerm is positioned to be a key player in shaping the future of healthcare by leveraging its expertise in drug-device combination therapies.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $75.00M | - | 07 Dec 2016 | |
| Post-IPO Equity | $77.00M | - | 15 Jul 2015 | |
| Venture Round | $16.00M | 1 | The Elias Group | 21 Aug 2014 |
| Series A | $2.50M | 1 | Robert Taub | 23 Jul 2007 |
No recent news or press coverage available for NeuroDerm, A Mitsubishi Tanabe Pharma Group Company.
We care about your data, and we'd love to use cookies make your experience better.
